A cancer vaccine leak wiped nearly a fifth of Moderna’s stock value off the board before anyone outside the room knew the shot actually worked.
Quick Take
- Embargoed melanoma vaccine data leaked online ahead of a scheduled presentation at the European Society for Medical Oncology congress.
- Moderna shares fell about 18%, with some reports citing an intraday drop near 25%.
- The full results, released early, showed the vaccine plus Keytruda cut the risk of recurrence or death by 42%.
- An oncology news outlet posted the data first; the European Society for Medical Oncology confirmed a breach and opened an investigation.
What Leaked, and Who Posted It First
Days before Merck and Moderna were set to present their melanoma vaccine data at the European Society for Medical Oncology congress, partial trial results showed up online. Contemporaneous reporting pointed to the site Oncology Central as the source of the early post, which was later taken down but not before screenshots spread across social media. The European Society for Medical Oncology confirmed the embargo had been broken and said it released the information itself since it was already public.
Once the leak spread, Merck and Moderna made a decision companies rarely get to control: they moved up their own announcement. Instead of waiting for the planned Saturday session, the companies posted the full phase 3 dataset on Thursday, turning a damage-control moment into an early disclosure. That timing matters because it shaped how investors first digested incomplete numbers before the full picture arrived.
The Actual Trial Results Tell a Different Story
The finished data looked nothing like a failure. Merck and Moderna reported the vaccine, known as intismeran autogene, combined with Keytruda cut the risk of melanoma recurrence or death by 42% compared with Keytruda alone, with a hazard ratio of 0.58. At two years, 82.2% of combination patients remained alive without recurrence, versus 70% on Keytruda alone, and the combination also lowered the risk of distant spread or death by 38%.
Safety data showed treatment-related side effects in 95.8% of combination patients compared with 90% on Keytruda alone, and the companies said no new safety signals turned up during the trial. That gap is worth watching, but it does not point to a hidden danger. It reflects the expected trade-off of adding a second active treatment to an already approved therapy.
Why Wall Street Sold First and Asked Questions Later
None of that stopped the stock slide. Moderna shares dropped roughly 18% after the partial leak circulated, with some accounts describing an intraday swing closer to 25%. The sell-off happened before the full dataset confirmed the drug worked, which tells you something about how skittish biotech investors have become after years of hype cycles and disappointing follow-through from early-stage cancer therapies.
Analysts tied much of the drop to sky-high expectations built up before the data even arrived, plus lingering uncertainty about whether the vaccine’s benefit would extend beyond melanoma. In other words, a strong result still disappointed traders who had priced in something even bigger. That is a market story about expectations, not a verdict on the medicine itself.
The Bigger Pattern Behind Clinical Trial Leaks
This is not the first time a conference embargo has broken down, and it will not be the last. Clinical trial disclosure has a documented history of selective reporting, delayed publication, and gaps between what regulators review and what the public eventually reads. That broader pattern does not prove anyone hid bad news here. It does explain why skeptical investors and doctors reflexively brace for the worst the moment embargoed data appears out of sequence.
What remains unresolved is who leaked the information and why. The European Society for Medical Oncology said it was investigating and suggested it may have identified the source, but no public accounting of responsibility has surfaced. Until that happens, the episode stands as a case study in how fragile embargo systems are, and how quickly markets punish uncertainty even when the underlying science holds up.
For patients watching this trial, the headline is straightforward: a personalized cancer vaccine paired with an existing immunotherapy meaningfully improved outcomes in resected melanoma. The leak scrambled the rollout and rattled shareholders, but it did not change what the data actually showed once everyone finally saw the whole picture.
Sources:
genomeweb.com, finance.yahoo.com, fiercebiotech.com, managedhealthcareexecutive.com, targetedonc.com
